Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks
With a US FDA endorsement, the drug – soon to join AbbVie’s portfolio under the companies’ $63bn merger – is the first oral option in its class and the first CGRP inhibitor approved to stop a migraine when it strikes.
You may also be interested in...
With an FDA approval decision for preventing episodic migraines expected during Q3, atogepant would add an oral CGRP antagonist to classmate Ubrelvy for acute attacks and Botox for prevention of chronic episodes.
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.